Eikon Therapeutics, Inc. (NASDAQ:EIKN) Given Average Rating of “Hold” by Analysts

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have been assigned an average rating of “Hold” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $25.20.

A number of research analysts recently weighed in on EIKN shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eikon Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday. Finally, Wedbush cut their target price on Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a research note on Tuesday, May 12th.

Eikon Therapeutics Trading Down 0.1%

Shares of EIKN opened at $9.55 on Thursday. The stock has a market capitalization of $517.03 million and a PE ratio of -3.88. Eikon Therapeutics has a fifty-two week low of $7.90 and a fifty-two week high of $17.40. The business has a 50-day simple moving average of $10.06.

Eikon Therapeutics (NASDAQ:EIKN) last released its earnings results on Monday, March 30th. The company reported ($26.23) earnings per share (EPS) for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.